TABLE 3.
Crude Outcomes
| RCRI 0 | RCRI 1 | RCRI 2 | RCRI 3 | RCRI ≥4 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| BB− (n = 50,457) |
BB+ (n = 23,447) |
BB− (n = 18,971) |
BB+ (n = 16,435) |
BB− (n = 5,221) |
BB+ (n = 7,507) |
BB− (n = 1,296) |
BB+ (n = 2,566) |
BB− (n = 306) |
BB+ (n = 728) |
p | |
| Length of stay, median (IQR) | 7 (5–11) | 8 (5–12) | 8 (5–12) | 9 (5–13) | 8 (5–12) | 9 (5–13) | 7 (4–11) | 9 (6–13) | 6 (4–12) | 9 (5–14) | <0.001 |
| Missing, n (%) | 366 (0.7) | 175 (0.7) | 123 (0.6) | 109 (0.7) | 57 (1.1) | 45 (0.6) | 15 (1.2) | 20 (0.8) | 3 (1.0) | 6 (0.8) | |
| 30-d Cause, n (%) | 3,476 (6.9) | 535 (2.3) | 2,700 (14.2) | 652 (4.0) | 1,340 (25.7) | 451 (6.0) | 499 (38.5) | 220 (8.6) | 164 (53.6) | 64 (8.8) | <0.001 |
| 30-d Cause-specific mortality | |||||||||||
| Cardiovascular event, n (%) | 1,143 (2.3) | 212 (0.9) | 1,149 (6.1) | 287 (1.7) | 643 (12.3) | 221 (2.9) | 264 (20.4) | 115 (4.5) | 82 (26.8) | 36 (4.9) | <0.001 |
| Respiratory failure, n (%) | 659 (1.3) | 82 (0.3) | 461 (2.4) | 87 (0.5) | 216 (4.1) | 70 (0.9) | 66 (5.1) | 23 (0.9) | 16 (5.2) | 5 (0.7) | <0.001 |
| Cerebrovascular event, n (%) | 92 (0.2) | 15 (0.1) | 33 (0.2) | 11 (0.1) | 5 (0.1) | 4 (0.1) | 3 (0.2) | 0 (0.0) | 1 (0.3) | 1 (0.1) | <0.001 |
| Sepsis, n (%) | 73 (0.1) | 10 (0.0) | 43 (0.2) | 12 (0.1) | 30 (0.6) | 6 (0.1) | 9 (0.7) | 4 (0.2) | 1 (0.3) | 2 (0.3) | <0.001 |
| Multiorgan failure, n (%) | 1,340 (2.7) | 191 (0.8) | 929 (4.9) | 225 (1.4) | 423 (8.1) | 134 (1.8) | 142 (11.0) | 73 (2.8) | 63 (20.6) | 19 (2.6) | <0.001 |
| Unknown, n (%) | 169 (0.3) | 25 (0.1) | 85 (0.4) | 30 (0.2) | 23 (0.4) | 16 (0.2) | 15 (1.2) | 5 (0.2) | 1 (0.3) | 1 (0.1) | <0.001 |
Length of stay is measured in days.
BB−, no β-blocker therapy; BB+, ongoing β-blocker therapy; IQR, interquartile range.